Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions
Anovulation
Interventions
DRUG

Highly Purified Urofollitropin

for Injection

DRUG

Recombinant Human Follitropin Alfa

for Injection

Trial Locations (12)

Unknown

Chinese PLA General Hospital, Beijing

Navy General Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou

The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou

Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology, Wuhan

The First Affiliated Hospital with Nanjing Medical University, Nanjing

ShengJing Hospital of China Medical University, Shenyang

Sichuan Provincial People's Hospital, Chengdu

Tianjin Medical University General Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT01923194 - Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females | Biotech Hunter | Biotech Hunter